Ultragenyx Pharmaceutical RARE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $136M-2.2% | $207.28M+25.9% | $159.93M+14.7% | $166.5M+13.2% | $139M+27.7% | ||
| $187M+12.7% | $203.28M+8.2% | $216.21M+27.1% | $164.74M+2.0% | $166M-7.0% | ||
| $88M+1.1% | $87.94M+7.4% | $86.62M+7.8% | $86.65M+7.5% | $87M+11.3% | ||
| -$169M-18.2% | -$113.28M+7.4% | -$170.89M-29.5% | -$107.89M+7.3% | -$143M+13.5% | ||
| -124.3%-21.4pp | -54.7%+19.6pp | -106.9%-12.2pp | -64.8%+14.3pp | -102.9%+49.0pp | ||
| $6M-14.3% | $6.51M-35.2% | $5.86M-45.4% | $5.79M-21.7% | $7M-20.7% | ||
| -$184M-22.7% | -$127.69M+3.9% | -$179.54M-34.8% | -$114M+12.8% | -$150M+11.9% | ||
| $1M0.0% | $870K+127% | $873K+188% | $947K+10.4% | $1M+120% | ||
| -$185M-22.5% | -$128.56M+3.5% | -$180.41M-35.1% | -$114.95M+12.6% | -$151M+11.5% | ||
| -136%-27.4pp | -62%+18.9pp | -112.8%-17.1pp | -69%+20.5pp | -108.6%+48.2pp | ||
| -$1.84-17.2% | -$1.28+7.2% | -$1.81-29.3% | -$1.17+23.0% | -$1.57+22.7% | ||
| -$1.84-17.2% | -$1.28+7.2% | -$1.81-29.3% | -$1.17+23.0% | -$1.57+22.7% | ||
| 100.6M+4.5% | 98.6M+9.0% | 99.8M+4.5% | 98.5M+13.7% | 96.3M+14.3% | ||
| 100.6M+4.5% | 98.6M+9.0% | 99.8M+4.5% | 98.5M+13.7% | 96.3M+14.3% | ||
| $30M+3.4% | $29.35M+70.9% | $27.99M+33.2% | $23M+8.1% | $29M+65.4% | ||
| $305M+8.2% | $320.56M+11.7% | $330.82M+21.9% | $274.38M+4.2% | $282M+2.9% | ||
| $21M+50.0% | $19.47M+25.8% | $14.15M-10.0% | $14.04M-12.0% | $14M-11.7% | ||
| $136M-2.2% | $207.28M+25.9% | $159.93M+14.7% | $166.5M+13.2% | $139M+27.7% | ||
| -$169M-18.2% | -$113.28M+7.4% | -$170.89M-29.5% | -$107.89M+7.3% | -$143M+13.5% | ||
| -$161M-20.1% | -$104.5M+7.3% | -$162.28M-31.7% | -$99.28M+7.6% | -$134M+14.4% | ||
| -$161M-20.1% | -$104.5M+7.3% | -$162.28M-31.7% | -$99.28M+7.6% | -$134M+14.4% | ||
| -118.4%-22.0pp | -50.4%+18.1pp | -101.5%-13.1pp | -59.6%+13.5pp | -96.4%+47.4pp | ||
| -$169M-18.2% | -$113.28M+7.4% | -$170.89M-29.5% | -$107.89M+7.3% | -$143M+13.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Ultragenyx Pharmaceutical's profit margins?
- Gross margin is 97.2% and operating margin is -83.8%, with a -90.9% net margin.
- Where does Ultragenyx Pharmaceutical's income statement data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.